Analysts have been eager to weigh in on the Healthcare sector with new ratings on Wright Medical Group (NASDAQ: WMGI) and Assembly Biosciences (NASDAQ: ASMB).
Wright Medical Group (NASDAQ: WMGI)
In a report released today, Craig Bijou from Cantor Fitzgerald reiterated a Buy rating on Wright Medical Group (NASDAQ: WMGI), with a price target of $30. The company’s shares closed yesterday at $27.24.
Bijou wrote:
“We reiterate our Overweight rating and a 12-month price target of $30 on shares of WMGI. We think WMGI is positioned to outperform expectations in 2018 with multiple drivers across each of its three primary segments (lower extremities, upper extremities, and biologics) to accelerate growth. We see WMGI’s valuation as attractive as we expect innovative products to help WMGI to capitalize on the evolving market trends. Valuation Summary We base our $30 price target on a 4.5x EV/Sales multiple on our 2019.”
According to TipRanks.com, Bijou is a 4-star analyst with an average return of 29.0% and a 67.7% success rate. Bijou covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and Stryker Corporation.
Currently, the analyst consensus on Wright Medical Group is Moderate Buy and the average price target is $31, representing a 13.8% upside.
In a report released today, Leerink Partners also reiterated a Buy rating on the stock with a $32 price target.
See today’s analyst top recommended stocks >>
Assembly Biosciences (NASDAQ: ASMB)
In a report released today, Gbola Amusa from Chardan Capital maintained a Hold rating on Assembly Biosciences (NASDAQ: ASMB), with a price target of $50. The company’s shares closed yesterday at $47.73.
Amusa said:
“We have some concerns on the sensitivity of the trial readouts, however. KOLs and management indicated that, while better techniques to measure HBV RNA are in development, current assays are not very sensitive, and it is unclear how viral markers in the serum relate to clearance of cccDNA in infected hepatocytes. Therefore, to us, the key data may come at some point beyond 2019, when the open label extension study monitors patients off therapy for 6 months to test for a complete cure (or when Assembly tests its more potent 2nd-generation CpAM, ABI-H2158). We note one KOL at the event, when asked if combination therapy has a real chance to succeed, was confident in the logic but emphasized the urgent need for data to support the hypothesis. Until such time as these data arrive, we see potentially better value in cheaper comps in the HBV space.”
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 26.4% and a 55.7% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Applied Genetic Technologies.
Currently, the analyst consensus on Assembly Biosciences is Moderate Buy and the average price target is $62.75, representing a 31.5% upside.
In a report released today, B.Riley FBR also reiterated a Hold rating on the stock with a $42 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
